|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inherited thrombophilia occurred in 20 (23.8%) MINOCA patients and in 13 (15.5%) with CS (P = 0.17), without any difference in the parameters except for elevated lipoprotein (a) that was less common in MINOCA (21.4 vs 39.3%, P = 0.012).
|
31133433 |
2019 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) was the factor most often abnormal in the thrombophilia group of all factors tested (8/19, 42%), regardless of migraine type or gender.
|
30486734 |
2018 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated plasma levels of lipoprotein(a) [Lp(a)] are an independent risk factor for the development of cardiovascular disease and associated with hypercoagulable states.
|
28901563 |
2017 |
|
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upon further investigation of the thrombophilia, the increase in lipoprotein(a) levels found in the mother and infant enabled the diagnosis of hyperlipoprotein(a) and the administration of appropriate therapy.
|
23247586 |
2013 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study 443 consecutive patients with a first episode of VTE and 304 matched healthy controls underwent laboratory screening for thrombophilia, including natural anticoagulants, factor V Leiden and prothrombin G20210A polymorphisms, antiphospholipid antibodies, homocysteine, factor VIII, and lipoprotein(a).
|
22422337 |
2012 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty-one patients with a first episode of a retinal artery occlusion underwent complete ophthalmic examination, routine blood testing and specific laboratory tests for thrombophilia, such as fasting and postmethionine homocysteine, lipoprotein(a), plasminogen activator inhibitor-1, factor VIII, factor V Leiden, factor II G20210A polymorphism, lupus anticoagulant and anticardiolipin antibodies.
|
17473572 |
2007 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, to compare the rate of elevated alpha2MG and prothrombotic risk factors [factor V G1691A, prothrombin G20210A, raised lipoprotein (a)] between patients and controls and to evaluate the interaction between elevated alpha2MG levels and other thrombophilias, odds ratios (ORs) together with 95% confidence intervals (CIs) were estimated using a logistic regression model.
|
17403113 |
2007 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Screening for hypercoagulability revealed 2 known risk factors: a mutation in the prothrombin gene and elevated lipoprotein a.
|
15833890 |
2005 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We carried out serologic measures of thrombophilia (homocysteine, anticardiolipin antibodies [ACLA] immunoglobulin G and immunoglobulin M, lupus anticoagulant, factor VIII, factor XI, protein C, total and free protein S, antithrombin III) and hypofibrinolysis (plasminogen activator inhibitor activity [PAI-Fx], lipoprotein[a]).
|
16154434 |
2005 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After confirming clinically suspected thromboembolism with suitable imaging methods, pediatric patients should be screened for common gene mutations (factor V G1691A, prothrombin G20210A and MTHFR C677T genotypes), rare genetic deficiencies (protein C, protein S, antithrombin, and plasminogen), and new candidates for genetic thrombophilia causing elevated levels of lipoprotein(a), and homocysteine, and probable genetic risk factors (elevations in fibrinogen, factor IX, and factor VIIIC, and decreases in factor XII).
|
12172465 |
2002 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the role of inherited thrombophilia in the development of central venous line (CVL)-related thrombosis, the following parameters were determined in 77 pediatric-oncologic patients with CVL: activated protein C (APC)-ratio, factor V (FV) G1691A and prothrombin G20210A mutation, protein C, protein S, antithrombin, coagulation factor XII, lipoprotein (a) and homocysteine.
|
10650856 |
1999 |